Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Antisense therapy in oncology: new hope for an old idea?

Official URL:https://doi.org/10.1016/S0140-6736(01)05629-X
PubMed:View item in PubMed
Creators Name:Tamm, I. and Doerken, B. and Hartmann, G.
Journal Title:Lancet
Journal Abbreviation:Lancet
Volume:358
Number:9280
Page Range:489-497
Date:11 August 2001
Keywords:Antineoplastic Agents, Antisense Oligodeoxyribonucleotides, Antisense Oligonucleotides, Clinical Trials as Topic, Drug Design, In Vitro Techniques, Isoenzymes, Messenger RNA, Neoplasms, Oligonucleotides, Phosphorothioate Oligonucleotides, Protein Kinase C, Protein Kinase C-alpha, Proto-Oncogene Proteins c-bcl-2, Thionucleotides, Animals
Abstract:There is a potential role for antisense oligonucleotides in the treatment of disease. The principle of antisense technology is the sequence-specific binding of an antisense oligonucleotide to target mRNA, resulting in the prevention of gene translation. The specificity of hybridisation makes antisense treatment an attractive strategy to selectively modulate the expression of genes involved in the pathogenesis of diseases. One antisense drug has been approved for local treatment of cytomegalovirus-induced retinitis, and several antisense oligonucleotides are in clinical trials, including oligonucleotides that target the mRNA of BCL2, protein-kinase-C alpha, and RAF kinase. Antisense oligonucleotides are well tolerated and might have therapeutic activity. Here, we summarise treatment ideas in this field, summarise clinical trials that are being done, discuss the potential contribution of CpG motif-mediated effects, and look at promising molecular targets to treat human cancer with antisense oligonucleotides.
ISSN:0140-6736
Publisher:Lancet (U.K.)
Item Type:Review

Repository Staff Only: item control page

Open Access
MDC Library